Advertisement
Canada markets closed
  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • Bitcoin CAD

    87,452.61
    +1,820.60 (+2.13%)
     
  • CMC Crypto 200

    1,367.25
    +54.63 (+4.16%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     
  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Amarin Full Year 2022 Earnings: US$0.26 loss per share (vs US$0.02 profit in FY 2021)

Amarin (NASDAQ:AMRN) Full Year 2022 Results

Key Financial Results

  • Revenue: US$369.2m (down 37% from FY 2021).

  • Net loss: US$105.8m (down from US$7.73m profit in FY 2021).

  • US$0.26 loss per share (down from US$0.02 profit in FY 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Amarin Earnings Insights

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 13% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Amarin has 3 warning signs we think you should be aware of.

ADVERTISEMENT

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here